An attenuated strain of Salmonella typhimurium was used as a vehicle for oral gene therapy against murine tumor. Eukaryotic expression vectors containing genes of human interleukin-12 (hIL-12), human granulocyte/macrophage colonystimulating factor (hGM-CSF), mouse (m)IL-12, mGM-CSF and green fluorescent protein (GFP) were used to transform attenuated Salmonella (SL3261), and such transformants were administered orally to BALB/c and C57BL/6 mice. As a reporter gene, GFP expression in murine liver, spleen, tumor, intestine and kidney was confirmed by confocal and flow cytometry. Soluble cytokines were detected in murine sera, and the concentrations were much higher than those of the control, which contributed to the increased number of cytotoxic T cells and prolongation of survival. Oral cytokine gene therapy using live attenuated Salmonella demonstrated a significant protection against the development of two unrelated murine tumors. These results suggest that such gene therapy has the potential to be simple, effective and (above all) safe against tumor.
Gene therapy for cancer is the object of intense investigation. Both GM-CSF and IL-12 are considered to have antitumor effects. [1] [2] [3] GM-CSF is a naturally occurring growth factor that is produced by a variety of cells in response to various immune or inflammatory stimuli. GM-CSF activates neutrophils, eosinophils and macrophages to lyse tumor cells directly or to mediate antibody-dependent cellular cytotoxicity; it can increase MHC expression, thereby increasing recognition of tumor antigen. 4 In a comparative study in mice, the most potent stimulator of specific antitumor immunity was tumor cells engineered to secrete GM-CSF. 5 IL-12 is a heterodimeric cytokine produced predominantly by antigen-presenting cells in response to infection agents. IL-12 stimulates the proliferation of activated NK and T cells and induces IFN-␥ production from them. IL-12 can also enhance the cytotoxic activity of NK cells and promote the generation of CTLs. 6 The systemic administration of recombinant IL-12 or GM-CSF protein has shown profound antitumor effects in animal models, but their clinical applications have been associated with significant side effect. 6, 7 In our research, we planned to develop a new gene delivery method using live attenuated Salmonella typhimurium (ST), which might avoid the costly need for ex vivo culture and administration of virus. Using live but attenuated ST allows the bacterium to penetrate the epithelial M cells and reach the Peyer's patches. During the process of phagocytosis of ST in Peyer's patches, a plasmid containing the encoded gene in the ST would be released into the cytosol and integrated into the nucleus. This could then lead to expression of the encoded gene in the host cells under the control of the eukaryotic promoter. 8, 9 This opens up the exciting possibility of oral gene therapy against tumor using ST as vehicle.
In the current study, we transferred the IL-12 and GM-CSF genes into STs and administered them orally to mice to induce cytokine expression in murine tissues. This oral gene therapy resulted in a high degree of protection against the development of two unrelated murine tumors. These results suggest that oral administration of IL-12 and GM-CSF genes using attenuated ST may work as a simple, effective and safe gene therapy against tumor
MATERIAL AND METHODS

Cells and mice
Lewis lung cancer cells derived from C57BL/6 mice and 4T1 mammalian cancer cells derived from BALB/c mice were cultured in 90% RPMI-1640 with L-glutamine medium supplemented with 10% FBS at 37°C in a humidified 5% CO 2 atmosphere. Four to 6-week-old female BALB/c (H-2 d ) and C57BL/6 (H-2 b ) mice were purchased from the Animal Institute of the Academia Sinica and kept under standard conditions according to institutional guidelines.
Bacterial strains, plasmids and media
The auxotrophic Salmonella typhimurium LB5000 (LT2 Trp MetE rpsl flaA ect, R ϩ M Ϫ for all three systems) and SL3261 (WARY hisG 46 aroA del 407 Fusaricres etc R ϩ M ϩ ) were kindly provided by B.A.D. Stocker (Stanford University School of Medicine, Stanford, CA). Bacterial strains were routinely grown at 37°C in LB broth or agar supplemented with 100 g/ml of ampicillin or 50 g/ml of kanamycin when required.
The eukaryotic green fluorescent protein expression vector EGFPN1 (Clontech, Palo Alto, CA) was used to characterize gene transfer in vivo and also as a control treatment. Plasmids pCMVhIL-12, pCMVhGM-CSF, pCMVmIL-12 and pCMVmGM-CSF were gifts from N.S. Yang (Central Research Institute of Taiwan) and were used for gene therapy in tumor protection studies. To create the human GM-CSF expression plasmid pCMVhGM-CSF, the cDNA of hGM-CSF was subcloned into a pUC19 vector containing the immediate/early promoter intron A region of human CMV and the bovine growth hormone gene polyadenylation region. The pUC19 plasmid backbone was derived from a bluescript SK (ϩ) vector with an ampicillin-resistant gene. Plasmid pCMVmGM-CSF was created in the same way.
Construction of plasmids pCMVhIL-12 and pCMVmIL-12 was similar: the p35 and p40 subunits of hIL-12 (mIL-12) were linked tandemly in the same direction and each was driven by its own CMV immediate/early promoter/enhancer, an SV40 sd/sa intron sequence and a bovine growth hormone polyadenylation sequence.
The LB5000 was grown in 100 ml L broth (Sigma, St. Louis, MO) to an A 600 of 0.5, chilled on ice and harvested by centrifAbbreviations: cfu, colony-forming unit; CMV, cytomegalovirus; CTL, cytotoxic T lymphocyte; FITC, fluorescein isothiocyanate; GFP, green fluorescent protein; GM-CSF, granulocyte/macrophage colony-stimulating factor; IFN-␥, interferon-␥; IL-12, interleukin-12; NK, natural killer; ST, Salmonella typhimurium; SV40, simian virus 40. *Correspondence to: Department of Hematology, Zhujiang Hospital, First Military Medicial University, Guangzhou 501282, China. Fax: ϩ86-20-8430980. E-mail: XYK00@163.net ugation (10 min, 1000g at 4°C). The pellet was suspended in a final volume of 200 l in 10% glycerol. Aliquots (50 l) were mixed with 1-2 g DNA in a chilled microcentrifuge tube and transferred to chilled cuvettes (0.2 cm electrode gap). A single pulse of 12.5KV/cm (2.5 kV, 200 ⍀, 25 F) was applied and 0.5 ml of prewarmed LB was immediately added. The bacteria were transferred to 17 ϫ 100 mm polypropylene tubes and shaken for 1 hr at 37°C before being plated onto LB agar with 100 g/ml of ampicillin or 50 g/ml of kanamycin. 8, 10 After amplification of the colony, the plasmids were extracted from the transferred LB5000 and then introduced into SL3261, in the same fashion as for LB5000.
Oral administration protocols
Bacteria were grown overnight until they reached mid-log phase. They were then harvested by centrifugation (3,000g) and resuspended in 10% sodium bicarbonate buffer. Three times at 14-day intervals mice were gently fed the bacterial suspension (1 ϫ 10 8 cfu/mouse) in a volume of approximately 30 l. 11 Each group of mice received the corresponding strain of recombinant Salmonella. Groups (C57BL/mIL-12 ϩ mGM-CSF, C57BL/hIL-12 ϩ hGM-CSF, BALB/mIL-12 ϩ mGM-CSF and BALB/hIL-12 ϩ hGM-CSF received the mixture (30 l) of equal volumes (15 l) of the suspension of both strains. Control mice received the SL3261/EGFPN1 strain or buffer only.
Transfer of the expression plasmids to host cells
On the day of primary oral administration, tumor cells were inoculated subcutaneously in the shaved area of the right flank of 2 mice from each group. BALB/c mice received 3 ϫ 10 3 4T1 tumor cells; C57BL/6 mice received 1 ϫ 10 4 Lewis tumor cells. Twenty-eight days later, spleens, livers, kidneys, tumors and intestines were removed from these mice, and genomic DNA was extracted by the SDS/proteinase K/phenol method, according to Maki et al. 12 The primers used for amplification of the CMV promoter were sense 5Ј-cccagtacatgaccttatggg-3Ј and antisense 5Ј-ggagacttggaaatccccgt-3Ј. The expected size of the PCR product was 141 bp. 13 PCR was performed in a programmable thermal cycler (PerkinElmer, Norwalk, CT) as follows: denaturation at 94°C for 30 sec, annealing at 55°C for 30 sec and polymerization at 72°C 45 sec for 30 cycles. Specimens of GFP control and blank control groups were also prepared, made into frozen sections and detected for GFP under confocal microscopy.
GFP expression in murine tissues
On day 28 after primary administration, spleens were removed from 5 mice of each group from the GFP control and blank control groups and made into simple cell suspension. After lysis of the red blood cells, GFP-expressing cells were detected by a flow cytometer (Coulter, Hialeah, FL).
Tumor cell challenge
Six weeks after the first oral administration, 4 ϫ 10 5 4T1 tumor cells or 1 ϫ 10 6 Lewis tumor cells were inoculated subcutaneously in the shaved area of the right flank of BALB/c or C57BL/6 mice. Tumor establishment was determined by palpation. Each group consisted of 10 -15 mice.
On day 42, after primary administration, 20 l blood was collected from 5 mice of each group. Heparin was added as an antithrombin agent. After lysis of red blood cells, antibody-coated cells were enumerated by flow cytometry (Coulter). The following antibodies were used: FITC-conjugated rat anti-mouse CD3 (rat IgG2b K ), FITC-conjugated rat anti-mouse CD8 (rat IgG2a) and FITC-conjugated rat anti-mouse CD4 (rat IgG2a K ) (all from PharMingen, San Diego, CA).
Cytokine assay
Blood was collected from all mice before and after oral administration every 2 weeks. The blood samples were stored at 5°C for 12 hr. After coagulation, sera were collected by centrifugation (5 min, 2000g at 4°C). All samples were stored at Ϫ20°C. At the end of the experiment, samples of the same group that had been collected at the same time were pooled and tested by hGM-CSF, hIL-12, mGM-CSF, mIL-12 and mIFN-␥ sandwich ELISA kits (Endogen, Woburn, MA) with triplicate wells.
Statistics
The percentages of spleen cells expressing GFP and the CD3 ϩ
CD8
ϩ /CD3 ϩ CD4 ϩ ratios were analyzed for significance by one-way ANOVA, comparing among the different groups of mice. If the p-value was Ͻ 0.05, the comparisons between two groups were analyzed by the Student-Neuman-Keuls method.
RESULTS
GFP expression and distribution in murine tissues
We first examined expression of the GFP gene in murine tissues. Such expression could be detected under confocal microscopy in livers, kidneys, spleens, tumors and intestines of the SL3261/ EGFPN1 orally treated mice. Spleens and tumors expressed more GFP than other tissues. The percentages of spleen cells expressing GFP were 3.01 Ϯ 0.29% and 3.03 Ϯ 0.36% in C57BL/6 mice and BALB/c mice, respectively, significantly higher than that of the blank control (F ϭ 55.421, p ϭ 0.000).
From confocal microscopic examination it could also be seen that GFP expression seemed to gather in one site, especially in tumor. The reason might be that macrophage cells are the most important cells in the phagocytosis of ST and expression of GFP, which secreted certain chemotactic factors that kept the cells at one site.
Characterization of in vivo gene transfer
To confirm the transduction of the somatic cells, genomic DNA was isolated from livers, spleens, intestines, kidneys and tumors. Because all the eukaryotic expression vectors used in this research were constructed with a CMV promoter, PCR was performed to amplify a portion of the CMV promoter as the proof of transfer. As had been expected, the PCR products of genomic DNA of the livers, spleens, intestines, kidneys and tumors of the treated groups and GFP groups were all 141 bp segments (Fig. 1) ; PCR products were not detected in DNA from blank control mice tissue. 
Increase of cytotoxic T cells in peripheral blood
It is known that CD3 ϩ CD8 ϩ is the phenotype of CTLs, which play an important role in mediating the cellular immune response against tumor, especially in IL-12-treated mice. In vivo depletion of CD3 ϩ CD8 ϩ T cells, but not of CD3 ϩ CD4 ϩ T cells, abrogated the effect of IL-12 gene therapy. 14 Six weeks after the first oral administration, the karyocytes in the peripheral blood had not increased significantly compared with the control groups (data not shown). However, flow cytometry analysis showed that the CD3 ϩ CD8 ϩ /CD3 ϩ CD4 ϩ ratios of the treated groups of C57BL/6 mice were much higher than those of the GFP and blank control (F ϭ 27.99, p ϭ 0.000; Table I ), as were those in the BALB/c mice (F ϭ 4.05, p ϭ 0.003). There was no significant difference between the GFP and blank control groups. These results suggest that cytokine genes harboring Salmonella contributed to the differentiation of T cells toward the cytotoxic phenotype, which might result in improvement of the cellular immune response, helping to kill the invading tumor cells. ST alone had little effect.
Prolongation of survival time
Three days after inoculation with 1 ϫ 10 6 Lewis cancer cells, all C57BL/6 mice developed tumor, but 10 days after inoculation, the tumors of 7 mice had disappeared. Five of those mice had been treated with SL3261/mGM-CSF, and another 2 were given both SL3261/mGM-CSF and SL3261/mIL-12. To test whether the mice possessed the memory T cells to counteract the tumor cells, the 7 tumor-free mice received a second challenge (2 ϫ 10 6 Lewis cancer cells), None of them developed tumor. The survival time of the treated groups was much longer than that of the GFP and blank control groups (Fig. 2) . No tumor in BALB/c mice disappeared, but the survival time also tended to be prolonged. It seemed that BALB/c mice had a lower response to cytokine genes than C57BL/6 mice. Of both C57BL/6 mice and BALB/c mice, the murine cytokine gene-treated groups tended to have a higher survival rate. To our surprise, the combination of GM-CSF and IL-12 did not show a stronger effect than IL-12 or GM-CSF alone in the prolongation of the survival time. They seemed to counteract each other. The GFP control and blank control groups showed no significant difference in survival time. This might mean that ST alone could not protect the body from tumor invasion.
Detection of hIL-12 and hGM-CSF in sera
The concentration of hIL-12 (and hGM-CSF) in BALB/c mice was almost the same as that in C57BL/6 mice (Fig. 3) . Both concentrations reached a peak at 2-4 weeks after oral administration and decreased gradually. At 10 -12 weeks, such concentrations reached normal levels. These variations might be the results of recognition and clearance of the heterogenous antigens, presumably operating as follows: after oral administration the exogenous gene was expressed in epithelial cells of the intestine. When the Salmonella reached the lymphatic system, spread to tissues all over the mice and was expressed there, cytokine serum concentrations increased continuously. When they reached a certain level, they were recognized, and antibodies were produced to clear them.
Detection of mGM-CSF and mIL-12 in sera
The variations in mGM-CSF and mIL-12 concentrations in C57BL/6 mice were much more complicated than those of hGM-CSF and hIL-12. They increased, decreased and then increased again (Fig. 4) . mGM-CSF and mIL-12 were murine cytokines. It was assumed that their production was under control of the negative response of the body and that their antibodies were not easily induced. Therefore, mGM-CSF and mIL-12 concentrations remained at high levels even at 10 -12 weeks after primary oral 1 C57BL/6 mice were orally administered either 10% sodium bicarbonate buffer (C57BL/blank), SL3261/EGFPN1(C57BL/GFP), SL3261/pCMVmGM-CSF(C57BL/mGM-CSF), SL3261/pCMVmIL-12(C57BL/mIL-12), both SL3261/pCMVmIL-12 and SL3261/pCMVmGM-CSF (C57BL/mIL-12 ϩ mGM-CSF), SL3261/pCMVhGM-CSF (C57BL/hGM-CSF), SL3261/pCMVhIL-12 (C57BL/hIL-12) or both SL3261/pCMVhIL-12 and SL3261/pCMVhGM-CSF (C57BL/ hIL-12 ϩ hGM-CSF), 3 times at 14-day intervals. Six weeks after the first oral administration of 20 l, blood was collected from 5 mice of each group. After lysis of the red blood cells, antibodies were added. administration. The concentration patterns of mGM-CSF and mIL-12 in BALB/c mice were similar.
It was previously reported that target gene could be expressed in a few hours in the intestine after oral administration with Salmonella, but about 28 days elapsed between the first oral administration and the start of gene expression in other tissues, 10 which might explain why the concentrations of mGM-CSF and mIL-12 start to rise at about 6 -8 weeks after the first oral administration, although the peak mIL-12 concentration came later in the C57BL/mIL-12 group than in the C57BL/mIL-12 ϩ mGM-CSF group. Some of the supposed reasons for this possibly complex mechanism are as follows: perhaps in the C57BL/mIL-12 group IFN-␥, which was upregulated by mIL-12, acted in synergy with other stimuli, suggesting an amplification loop for IL-12 production, 15 whereas in the C57BL/mIL-12 ϩ mGM-CSF group, mIL-12 production might have been influenced by even more factors. For example, GM-CSF could have induced the secretion of IL-1, which could synergize with IL-12 to induce considerable IFN-␥ production by T cells; 16, 17 then IFN-␥ in turn could have upregulated IL-12 production, 15 whereas GM-CSF itself could have inhibited IL-12 production. 18 All these influences might have caused the difference in mIL-12 variations between C57BL/mIL-12 ϩ mGM-CSF and C57BL/mIL-12 mice.
Detection of mIFN-␥ in sera
IFN-␥ is the effector molecule that mediates the antitumor effect of IL-12. Therefore, IFN-␥ activity might reflect that of IL-12. In both C57BL/mIL-12 and C57BL/mIL-12 ϩ mGM-CSF mice, the mIFN-␥ concentration began to rise at about 6 -8 weeks after the first oral administration, the same time as mIL-12. Variations in mIFN-␥ concentration were similar in the corresponding groups of BALB/c mice. However, in SL3261/hIL-12-treated and SL3261/ hIL-12 ϩ SL3261/hGM-CSF-treated C57BL/6 mice, mIFN-␥ levels changed in a different fashion, corresponding to that of the hIL-12 group (Fig. 5) .
The concentrations of the five cytokines detected were much higher in treated groups than in GFP and blank control groups, possibly showing that cytokine secretion upregulated the immune function of the mice and mediated the antitumor effect. These results indicated the efficiency of oral gene therapy using live attenuated Salmonella.
DISSCUSSION
After chemotherapy or irradiation there are still 10 6 -10 9 tumor cells left, which are the source for relapse. However, chemotherapy or irradiation to eliminate all these tumor cells would do more Presence of transduced hIL-12 cytokine in the sera of C57BL/6 mice. C57BL/6 mice were orally administered either 10% sodium bicarbonate buffer (C57BL/ Blank), SL3261/EGFPN1 (C57BL/GFP), SL3261/pCMVhGM-CSF (C57BL/hGM-CSF), SL3261/pCMVhIL-12 (C57BL/hIL-12) or both SL3261/pCMVhIL-12 and SL3261/pCMVhGM-CSF (C57BL/hIL-12 ϩ hGM-CSF) 3 times at 14-day intervals. Sera samples were taken from these mice every 2 weeks. At the end of the experiment, samples from the same group collected at the same time were pooled and quantified using hGM-CSF and hIL-12 cytokine ELISA kits. Data shown are mean Ϯ SE from 2 independent oral application experiments with triplicate wells. The corresponding groups of BALB/c mice showed similar results. Presence of transduced mIL-12 cytokine in the sera of C57BL/6 mice. C57BL/6 mice were orally administered either 10% sodium bicarbonate buffer (C57BL/ Blank), SL3261/EGFPN1 (C57BL/GFP), SL3261/pCMVmGM-CSF (C57BL/mGM-CSF), SL3261/pCMVmIL-12 (C57BL/mIL-12), or both SL3261/pCMVmIL-12 and SL3261/pCMVmGM-CSF (C57BL/ mIL-12 ϩ mGM-CSF) 3 times at 14-day intervals. Sera samples were taken from these mice every 2 weeks. At the end of the experiment, samples of the same group collected at the same time were pooled and quantified using mGM-CSF and mIL-12 cytokine ELISA kits. Data shown are mean Ϯ SE from 2 independent oral application experiments with triplicate wells. The corresponding groups of BALB/c mice showed similar results.
harm to normal tissues. Immunotherapy is perhaps the most promising way to remove minimal residual disease.
Cytokines are very important in mediating the immune system. Limitations associated with systemic administration of cytokines include the short half-life of many cytokines and the severe side effects commonly observed with direct administration. 4 Gene transfer might avoid some of the side effects, but it is costly, time-consuming and complicated. A new, safe and convenient way for clinical gene transfer is urgent.
It was previously demonstrated that Salmonella could mediate GFP expression in dendritic spleen cells about 28 days after the first oral administration. 10 We therefore chose 28 days after the first oral administration to test gene transfer and GFP expression in murine tissues. To our excitement, GFP expression could not only be detected in the spleen, but also in many other organs such as the intestine, kidney, tumor and liver. However, our results did not support the hypothesis that Salmonella possessed a tumor-targeting property, as reported by Low et al. 19 and Pawelek et al.: 20 tumor-targeted Salmonella exhibited tumor accumulation ratios in excess of 1000:1 compared with normal tissues, since gene transduction and GFP expression could be detected in almost all mouse organs, and GFP expression in the spleen was more wide-spread than that of the tumor. The different strains of Salmonella used in our research might have contributed to the difference in results, in addition to different methods for comparison and different murine tumor models, etc. At the same time, our results gave us an exciting indication that attenuated Salmonella was the best vector for cytokine gene expression, because it could cause expression at the sites where they could exert their maximum effect on lymphocytes and act directly on tumor cells.
It was previously shown that both IL-12 and GM-CSF have antitumor properties, 5, 21, 22 and other experiments had revealed that the combination of these two cytokines might amplify this effect. 23 It has recently been reported that GM-CSF could inhibit IL-12 P40 production by anti-CD40/IFN-␥-stimulated mouse Langerhans cells. 18 Our research has shown that the combination of IL-12 and GM-CSF did not increase the CD8 ϩ /CD4 ϩ ratio as much as that of IL-12 or GM-CSF alone. The survival time of IL-12 ϩ GM-CSF-treated groups was shorter than that of groups treated with GM-CSF alone. It seemed that IL-12 and GM-CSF did not act in synergy, but their counteracting effect was not significant either. The reason was not clear and the explanations might be various. Perhaps GM-CSF inhibited the secretion of IL-12, or vice versa, IL-12 inhibited tumor angiogenesis while GM-CSF counteracted it by stimulating endothelial cells to proliferate. 24, 25 According to Darji et al., 11 the CTL reaction induced by Salmonella started to increase 5 weeks after the first oral administration and continued to increase. Based on this result, we challenged the mice with tumor cells 6 weeks after the first oral administration. The recombinant Salmonella harboring either murine cytokine genes or human cytokine genes displayed significant antitumor effect. However, hGM-CSF and hIL-12 concentrations decreased to normal levels in a short time, whereas mGM-CSF and mIL-12 concentrations remained at high levels for a longer time, which might explain why there was a difference in survival time between the murine and human cytokine gene-treated groups. The regulatory mechanisms contributing to the variations in hGM-CSF, hIL-12, mGM-CSF and mIL-12 concentrations should be tested further.
The results of our research show that Salmonella mediated cytokine gene expression in vivo and exerted an antitumor effect. It was concluded that attenuated Salmonella could serve as a vector for oral gene therapy and provide a new safe and efficient way to treat cancer.
